Compare MBI & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | KALA |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 319.6M |
| IPO Year | 1994 | 2017 |
| Metric | MBI | KALA |
|---|---|---|
| Price | $5.78 | $0.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $31.50 |
| AVG Volume (30 Days) | 392.9K | ★ 6.5M |
| Earning Date | 05-07-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.04 | 41.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.48 | N/A |
| 52 Week Low | $3.86 | $0.23 |
| 52 Week High | $8.26 | $20.58 |
| Indicator | MBI | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 32.09 |
| Support Level | $4.73 | $0.23 |
| Resistance Level | $6.94 | $0.72 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 11.76 | 5.40 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. The U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiaries.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.